EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische Studie

Mega‐dose decitabine conditioning and prophylactic donor lymphocyte infusion for patients with relapsed/refractory AML with active disease at the time of allogeneic haematopoietic cell transplantation: A multicenter prospective phase II study

Meng Lv iD, Chen-Hua Yan, Rui Ma, Yun He, Yuan-Yuan Zhang, Zhi-Dong Wang, Yu-Hong Chen, Wei Han, Jun Kong iD, Ting-Ting Han, Jing Liu, Hao Zheng und 6 weitere

British Journal of Haematology · 2024

DOI: 10.1111/bjh.19781 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift British Journal of Haematology, 2024. Verfasst von Meng Lv und 17 weiteren Autor:innen. Beteiligte Einrichtung: Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Ke…. Hauptthemen laut MEDLINE: Decitabine, Hematopoietic Stem Cell Transplantation, Leukemia, Myeloid, Acute, Lymphocyte Transfusion. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Peking University Medicine Fund for world's leading discipline or discipline cluster development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients with relapsed/refractory acute myeloid leukaemia (R/R AML), especially those who failed in novel target agents are related to dismal survival. We developed a multi‐institutional, single‐arm, prospective phase II trial, to investigate intensified conditioning with ‘Mega‐Dose’ decitabine (MegaDAC) following allogeneic haematopoietic cell transplantation (allo‐HCT) for R/R AML. From 2019 to 2023, 70 heavily treated R/R AML patients in active disease were consecutively enrolled. Significantly, every patient ( n = 18) harbouring specific mutations exhibited no response to their best available target agents (BATs). Moreover, 74.3% of the enrolled patients did not reach remission following venetoclax‐based regimens. All patients underwent intravenous decitabine (400 mg/m 2 ) along with busulfan and cyclophosphamide. Median follow‐up was 26 months (8–65) after HCT. All engrafted patients achieved MRD negativity post‐HCT, with a median 3.3‐log reduction in recurrent genetic abnormalities. The regimen was well tolerated, without irreversible grades III–IV toxicity peri‐engraftment. The estimated 2‐year CIR was 29.6% (18.4%–41.7%) and the est‐2‐year NRM was 15.5% (7.8%–25.5%). The est‐2‐year LFS, OS, and GRFS were 55.0% (43.5%–69.4%), 58.6% (47.0%–73.0%), and 42.9% (31.9%–57.6%), respectively. Multivariate analysis showed that pre‐HCT drug exposures had no significant impact on primary outcomes. MegaDAC is highlighted as an effective and safe option for R/R AML in the new era of targeted therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DecitabineHematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcuteLymphocyte TransfusionTransplantation ConditioningAdultAgedFemaleHumansMaleMiddle AgedYoung AdultProspective StudiesRecurrenceTransplantation, HomologousDose-Response Relationship, Drug

Stichwörter der Autor:innen

R/R AMLallo‐HCTdecitabinemDLIrelapse

Substanzen

Decitabine

Autor:innen und Institutionen

  • Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, Chin…
  • Beijing Qinghe Hospital, Beijing, China.
  • Beijing Ludaopei Hematology Hospital, Beijing, China.
  • Peking-Tsinghua Center for Life Sciences, Beijing, China.
  • State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing, China.
  • Research Unit of Key Technique for Diagnosis and Treatments of Hematologic Malignancies, Chinese Academy of Medical Sciences, Beijing, China.

ORCID-Profile: Meng Lv, Jun Kong, Xiao-Dong Mo, Yu Wang, Lan-Ping Xu, Xiao-Hui Zhang, Xiao-Jun Huang

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • Peking University Medicine Fund for world's leading discipline or discipline cluster development
  • Beijing Nova Program
  • Peking University

Zitieren

APA

Lv, M., Yan, C. H., Ma, R., He, Y., Zhang, Y. Y., Wang, Z. D., Chen, Y. H., Han, W., Kong, J., Han, T. T., Liu, J., Zheng, H., Mo, X. D., Sun, Y. Q., Wang, Y., Xu, L. P., Zhang, X. H., & Huang, X. J. (2024). Mega‐dose decitabine conditioning and prophylactic donor lymphocyte infusion for patients with relapsed/refractory AML with active disease at the time of allogeneic haematopoietic cell transplantation: A multicenter prospective phase II study. British Journal of Haematology. https://doi.org/10.1111/bjh.19781

Vancouver

Lv M, Yan CH, Ma R, He Y, Zhang YY, Wang ZD, et al. Mega‐dose decitabine conditioning and prophylactic donor lymphocyte infusion for patients with relapsed/refractory AML with active disease at the time of allogeneic haematopoietic cell transplantation: A multicenter prospective phase II study. British Journal of Haematology. 2024. doi:10.1111/bjh.19781

BibTeX
@article{Lv2024,
  author = {Lv, Meng and Yan, Chen-Hua and Ma, Rui and He, Yun and Zhang, Yuan-Yuan and Wang, Zhi-Dong and Chen, Yu-Hong and Han, Wei and Kong, Jun and Han, Ting-Ting and Liu, Jing and Zheng, Hao and Mo, Xiao-Dong and Sun, Yu-Qian and Wang, Yu and Xu, Lan-Ping and Zhang, Xiao-Hui and Huang, Xiao-Jun},
  title = {Mega‐dose decitabine conditioning and prophylactic donor lymphocyte infusion for patients with relapsed/refractory AML with active disease at the time of allogeneic haematopoietic cell transplantation: A multicenter prospective phase II study},
  journal = {British Journal of Haematology},
  year = {2024},
  doi = {10.1111/bjh.19781}
}
Kostenlos starten →